FDA
Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite assurances of swift reviews under the FDA’s new Commissioner’s National Priority Voucher program.
FEATURED STORIES
After a tumultuous year, experts call for stability while anticipating the first fruits of policies intended to expedite approvals for rare disease drugs.
The FDA’s announcement that it will phase out in vivo testing requirements for monoclonal antibodies marks a seismic shift. Here’s how industry can adapt.
Policy initiatives have come fast and furious at the FDA this year. While guidances on rare diseases and vaccines have consumed most of the ink, policy shifts aimed at improving FDA efficiencies and reshoring U.S. manufacturing also got some attention. Here, BioSpace rounds up more than a dozen initiatives relevant to the biopharma industry.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
The approval of HAnano Surface in the United States has been executed in accordance with the new 510(k) legislation for medical devices.
A look at the latest batch of FDA approvals this year.
This could be the first step in a long journey that could amount to huge profitability for the iPhone maker.
Foundation Medicine’s sequencing diagnostics test for solid tumors that can detect cancer-causing mutations in 324 genes was approved by the FDA Thursday.
HIV patients have a new maintenance drug in their arsenal of medication.
A look at the 19 spine-related medical devices the FDA cleared in October.
The FDA approved a label expansion for Pfizer’s cancer drug Sutent to include the adjuvant treatment of adult patients at high risk of RCC following the surgical removal of the cancerous kidney.
Genentech scored two approvals from the FDA this week.
The drug will be used to prevent or reduce the frequency of bleeding episodes in certain patients.
The FDA approved Dynavax’s Heplisav-B, it’s first new hepatitis B vaccine in the U.S. in more than 25 years.